A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2004
12/02/2004	CA2525789A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
12/02/2004	CA2525130A1 Improved cytotoxic agents comprising new maytansinoids
12/02/2004	CA2524950A1 Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid
12/02/2004	CA2524936A1 Compositions and methods for the preparation of human growth hormone glycosylation mutants
12/02/2004	CA2524860A1 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
12/02/2004	CA2524707A1 Repeat sequence protein polymer active agent conjugates, methods and uses
12/02/2004	CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
12/02/2004	CA2469528A1 Peptide and peptide mimetic derivatives having integrin inhibitor properties iii
12/02/2004	CA2429891A1 Membrane fusion protein
12/01/2004	EP1481695A1 Formulations of hyaluronic acid for delivery of osteogenic proteins
12/01/2004	EP1481690A1 Therapeutic compositions including bio-availability enhancers
12/01/2004	EP1481687A1 Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
12/01/2004	EP1481686A1 Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
12/01/2004	EP1481677A1 Cosmetic and/or dermatological composition containing ascorbic acid or its derivatives stabilised by at least one amphiphilic polymer chosen from oligomers or polymers derived from polyisobutylene
12/01/2004	EP1481666A1 A composition for re-establishment of the vaginal ecosystem
12/01/2004	EP1481078A2 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
12/01/2004	EP1481057A1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host
12/01/2004	EP1481017A1 Biodegradable polymeric material for biomedical applications
12/01/2004	EP1480996A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
12/01/2004	EP1480990A1 Compounds for use as surfactants
12/01/2004	EP1480736A2 Microcapsules having high carotenoid content
12/01/2004	EP1480691A2 Agglomerated particles for aerosol drug delivery
12/01/2004	EP1480687A1 Modified phosphocalcic compound, injectable composition containing same
12/01/2004	EP1480682A1 Coupling proteins to a modified polysaccharide
12/01/2004	EP1480681A2 Coupling low-molecular substances to a modified polysaccharide
12/01/2004	EP1480680A2 Compositions of polymers
12/01/2004	EP1480679A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
12/01/2004	EP1480678A2 Treatment of ophthalmic disorders using urea and urea derivatives
12/01/2004	EP1480677A2 Composition for stabilizing hyaluronic acid
12/01/2004	EP1480673A1 A bioadhesive agent
12/01/2004	EP1480672A2 Compositions and compounds for use as a nicotine vaccine employing response selective agonist of an antigen-presenting cell receptor as a molecular adjuvant
12/01/2004	EP1480657A1 Polymers for delivering peptides and small molecules i in vivo /i
12/01/2004	EP1480653A2 Ribavirin syrup formulations
12/01/2004	EP1480652A1 Use of phospholipids in peritoneal dialysis
12/01/2004	EP1480651A1 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery
12/01/2004	EP1480650A1 Novel crystalline forms of the anti-cancer compound zd1839
12/01/2004	EP1480636A2 Self emulsifying drug delivery systems for poorly soluble drugs
12/01/2004	EP1480630A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
12/01/2004	EP1480626A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity
12/01/2004	EP1480624A2 Pharmaceutical tablet
12/01/2004	EP1480623A1 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
12/01/2004	EP1480621A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
12/01/2004	EP1480620A2 (ester)-lysolecithins in liposomes
12/01/2004	EP1480618A1 Sustained release drug formulations containing a carrier peptide
12/01/2004	EP1480616A1 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
12/01/2004	EP1480615A1 Formoterol superfine formulation
12/01/2004	EP1480517A2 Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
12/01/2004	EP1351991A4 Ternary biomolecule/polymer/surface-based immobilization systems
12/01/2004	EP1263761B1 Compounds for pdt
12/01/2004	EP1261355B1 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
12/01/2004	EP1240230A4 Swelling and deswelling polymer blends
12/01/2004	EP1214093B1 Method for producing a tablet made of isomaltulose, isomalt or isomalt variants and corresponding products
12/01/2004	EP1196383B1 Process for preparing amlodipine benzenesulphonate
12/01/2004	EP1173197B1 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
12/01/2004	EP1121449A4 Delivery system for porcine somatotropin
12/01/2004	EP1117386B1 Enteric and colonic delivery using hpmc capsules
12/01/2004	EP1059943B1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles
12/01/2004	EP1044688B1 Method for solubilizing pyridonecarboxylic acids and aqueous solutions containing pyridonecarboxylic acids
12/01/2004	EP0966974B1 Antibacterial composition for topical administration containing faropenem
12/01/2004	EP0953009B1 A process for preparing polymeric microgels
12/01/2004	CN1551872A Biologically active methylene blue derivatives
12/01/2004	CN1551785A Sustained release of microcrystalline peptide suspensions
12/01/2004	CN1551784A Prostaglandin compositions and methods of treatment for male erectile dysfunction
12/01/2004	CN1551771A Method and composition for treatment of cancer
12/01/2004	CN1551768A Substituted benzimidazole dosage forms and method of using same
12/01/2004	CN1551760A Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
12/01/2004	CN1551759A Oily thixotropic formulations
12/01/2004	CN1551758A Process for dispersing a fluid in solid particles
12/01/2004	CN1550525A Pigment composition and use in cosmetic, food and pharmaceutical preparations
12/01/2004	CN1550504A Process of high purity albumin production
12/01/2004	CN1550230A Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof
12/01/2004	CN1177787C Powder shape mannitol and process for preparing same
12/01/2004	CN1177762C Electrolysis purifying of calcium carbonate
12/01/2004	CN1177614C Slow releasing composition
12/01/2004	CN1177612C Composition for sustained release of non-aggregated erythropoietin
12/01/2004	CN1177610C Pharmaceutical composition for immunomodulation based on peptides and adjuvants
12/01/2004	CN1177594C Formulation for use in prevention of pathogen induced diseases including HIV and HSV
12/01/2004	CN1177583C Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
12/01/2004	CN1177582C Pharmaceutical aerosol compsn. contg. HFA227 and HFA 134a
11/2004
11/30/2004	US6825341 Treating polyamine with functionalized hemiacetal in presence of titanium isopropoxide and sodium borohydride; synthetic genetic vector
11/30/2004	US6825326 Antibody which specifically binds to prostate stem cell antigen on surface of carcinoma cells and is internalized within carcinoma cells to which it binds
11/30/2004	US6825234 Compositions and methods for amelioration of human female sexual dysfunction
11/30/2004	US6825206 Treatment of leukemia, solid tumors and brain glioma in mammals using the conjugates
11/30/2004	US6825203 Topical anesthetic/opioid formulations and uses thereof
11/30/2004	US6825179 Active ingredient combinations or adducts of cyclodextrins and quinones
11/30/2004	US6825178 Discovery that p. aeruginosa binds to the cystic fibrosis transmembrane conductance regulator (cftr)
11/30/2004	US6825166 Molecular conjugates for use in treatment of cancer
11/30/2004	US6824822 Residual solvent extraction method and microparticles produced thereby
11/30/2004	US6824793 Bioadhesive properties of the hyaluronic acid polymers decrease the rate of mucociliary clearance from the nasal cavity and thus allow a longer contact time between the antigen and the absorbing membrane
11/30/2004	US6824790 Capsule, tablet with enteric, protective coatings; bioavailability
11/30/2004	US6824782 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability
11/30/2004	US6824766 Drug delivery
11/30/2004	US6824763 Anti-fungal powder having enhanced excipient properties
11/30/2004	CA2396441C Diclofenamide suspension gel
11/30/2004	CA2298245C Matrix controlled release device
11/30/2004	CA2265461C Compositions and methods for topical application of therapeutic agents
11/25/2004	WO2004101776A2 Novel uses of ppar modulators and professional apcs manipulated by the same
11/25/2004	WO2004101756A2 Ovr110 antibody compositions and methods of use
11/25/2004	WO2004101740A2 Clotting factor-fc chimeric proteins to treat hemophilia
11/25/2004	WO2004101600A2 Novel poly(ethylene glycol) modified compounds and uses thereof

1 ... 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 ... 1712